Speakers

Expand/Collapse

Alejandro Rangel
Associate Professor of Medicine
Universidad Panamericana

Day Two

9:30 am | Panel Discussion: Comprehensively Analyzing the Impact of Aducanumab’s Approval for Alzheimer’s on the Regulatory Landscape for Neurodegenerative Disease

Andrea Crotti
Principal Scientist - Early Discovery
Takeda

Beth Hoffman
Founder, President & Chief Executive Officer
Origami Therapeutics

Day One

8:30 am | Exploring CNS Application of Protein Degraders to Determine Whether They Can be Utilized in a Selective Manner to Minimize Side Effects & Maximize Therapeutic Outcome

Chris Winrow
Vice President & Head of Translational Medicine
Cyclerion

Day Two

9:30 am | Panel Discussion: Comprehensively Analyzing the Impact of Aducanumab’s Approval for Alzheimer’s on the Regulatory Landscape for Neurodegenerative Disease

Track B - Day 1

2:00 pm | From Concept to Clinic: Targeting the Nitric Oxide-Soluble Guanylate Cyclase-cGMP Pathway for Neurodegenerative Diseases

Daniel Alkon
President –Research
Synaptogenix

Track B - Day 1

1:30 pm | Uncovering Bryostatin Targets Restoration of Synaptic Wiring Lost in Alzheimer’s Degeneration

David Bearss
Chief Scientific, Officer
Halia Therapeutics

Day Two

9:00 am | Targeting the NLRP3 Inflammasome for the Treatment of Alzheimer’s

Dimitry Ofengeim
Head of Precision Neurology & Neuroinflammation
Sanofi

Pre-Conference Discussion Day

Monday, March 28, 2022

8:02 am | Defining Approaches for Precision Neurology

George Tetz
Chief Executive Officer
CLS Therapeutics & The Human Microbiology Institute

Day One

9:00 am | Weaponizing the Microbiome Against Alzheimer’s Disease

Gergely Toth
Chief Executive Officer & Chief Scientific Officer
Cantabio

Day One

11:00 am | Deep Diving into Therapeutic Targeting of the DJ-1 Protein for the Treatment of Parkinson’s Disease

Graham Dempsey
Chief Scientific, Officer
Q-State Bio

Pre-Conference Discussion Day

Monday, March 28, 2022

1:03 pm | Investigating Therapeutic Discovery Platforms for Oligonucleotides Targeting Neurodegenerative Diseases

Habib Baghirov
Senior Scientific, Business Analyst
Roche

Day Two

9:30 am | Panel Discussion: Comprehensively Analyzing the Impact of Aducanumab’s Approval for Alzheimer’s on the Regulatory Landscape for Neurodegenerative Disease

Pre-Conference Discussion Day

Monday, March 28, 2022

8:03 am | Utilizing Innovative Delivery Technology to Move Across the Blood Brain Barrier & Optimize Precision Targeting of Neurons

Jamil Beg
Life Science, Venture Capitalist, & Entrepreneur
5am Ventures

Day Two

3:00 pm | Panel Discussion: The New Landscape in NDD investing: How the 2021 Events Have Changed Outlooks

Je Min Yoo
Chief Technology, Officer
Biographene

Track A - Day 1

2:00 pm | The New Target Journey: How to Progress from Target Identification & Illustrate Meaningful Effect in Pre-Clinical Models

Johannes Krupp
Research Program Director for Neurology
Servier

Pre-Conference Discussion Day

Monday, March 28, 2022

1:02 pm | Exploring RNA Targeted Approaches for Rare Movement Disorders

John Gustofson
Managing Director
AbbVie

Day Two

3:00 pm | Panel Discussion: The New Landscape in NDD investing: How the 2021 Events Have Changed Outlooks

John Hey
Chief Scientific Officer
Alzheon

Track B - Day 2

2:30 pm | Fluid & Imaging Biomarkers in ALZ-801 Development: A First-in-Class Oral Disease Modifying Agent for Alzheimer’s Disease

Jonathan Behr
Partner
Dementia Discovery Fund

Day Two

3:00 pm | Panel Discussion: The New Landscape in NDD investing: How the 2021 Events Have Changed Outlooks

Jonathan Proto
Principal Scientist
Sanofi

Track A - Day 1

1:30 pm | Learning How to Integrate Information on Cellular Communication & Pathways for a Multi-Omic Approach to Target Identification

Judy Walker
Chief Medical, Officer
Cerecin

Day One

9:30 am | Metabolic Dysfunction in Neurodegenerative Disorders: Spotlight on Parkinson’s, Huntington’s & Alzheimer’s

Katherine Deng
Principal Scientist
AbbVie

Track A - Day 2

1:30 pm | In Vitro Transcytosis Models for BBB targeting CNS Drug Screening

Keechan Ahn
Chief Scientific Officer
Astrogen

Day Two

11:30 am | Introducing a Novel Drug Assessment Through Brain Microdialysis Examining BBB Permeability

Lisa Shafer
Chief Scientific Officer
Cerebral Therapeutics

Day Two

11:00 am | Analyzing Translational Approaches for Brain Targeted Drug Delivery

Magdalene Moran
President & Chief Scientific Officer
Carraway Therapeutics

Day One

11:30 am | Enhancing Lysosomal Function as a Therapeutic Strategy for Parkinson’s Disease

Day Two

9:30 am | Panel Discussion: Comprehensively Analyzing the Impact of Aducanumab’s Approval for Alzheimer’s on the Regulatory Landscape for Neurodegenerative Disease

Manuel Sanchez-Felix
Senior Fellow, Novel Delivery Technologies
Novartis

Track B - Day 1

12:32 pm |
Analyzing Key Clinical Trial Updates

Marcy Taylor
Vice President of Research
Treventis

Track A - Day 2

1:00 pm | Discovery of Small Molecule Dual Inhibitors of Abeta & Tau Aggregation Using CCM Technology

Martin Tolar
Founder, President & Chief Executive Officer
Alzheon

Day One

3:30 pm | ALZ-801 Phase 3 Program: Lessons & The Path Forward in Developing Targeted Therapies for Alzheimer’s Disease

Melissa Geddie
Principal Scientist – Antibody Discovery
Biogen

Track A - Day 1

12:32 pm |
Streamlining Target Discovery

Michela Gallagher
Founder & Chief Executive Officer
Agene Bio

Day One

4:00 pm | HOPE4MCI - Exploring Hippocampal Overactivity Prevention in the Elderly

Michele Vendruscolo
Professor
University of Cambridge

Day Two

8:30 am | Targeting Abeta Oligomer Formation Using Small Molecules

Murali Gopalakrishnan
Global Head of Neuroscience Search & Evaluation
AbbVie

Day One

8:25 am | Chair’s Opening Remarks

Day Two

8:25 am | Chair’s Opening Remarks

Phllip Kong
Associate Director for Translational Medicine
Alector

Track A - Day 2

12:03 pm |
Closing the Translational Gap: Update on Neurodegenerative Disease Models & Imaging

Raj Ganesan
Senior Director -Protein Engineering & Antibody Discovery Research
Alector

Track B - Day 1

2:30 pm | Versatile Therapeutic Intervention Approaches to Modulate Microglial Activity for the Treatment of Neurodegenerative Disease

Raphael Lis
Assistant Professor in Regenerative & Reproductive Medicine & Director of the Starr Foundation Stem Cell Derivation Laboratory
Weill Cornell Medicine

Track A - Day 2

2:30 pm | Exploring the Generation of Vascularised & Perfusable Brain Organoid for Disease Modelling

Rob Shaffer
Founder
Enable Therapeutics

Pre-Conference Discussion Day

Monday, March 28, 2022

1:03 pm | Targeting Glycogen in Childhood Dementia with Expansion Potential to Larger Neurodegenerative Indications

Ross Jeggo
Global Head of Neuroscience & Immuno-Inflammation Therapeutic Aria
Servier

Day One

12:00 pm | Showcasing LRRK2 Inhibitors as Treatment for Parkinson’s Disease

Sharon Rosenzweig-Lipson
Vice President of Research & Development
AgeneBio

Stan Chamberlain
Chief Scientific Officer
T3D Therapeutics

Day One

4:30 pm | Deep Diving into the Development of a PPAR Delta/Gamma Agonist T3D-959 for Alzheimer’s Disease